Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics
Molecules · 2025
DOI: 10.3390/molecules30020212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Lorraine Gaenaelle Gé und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Odense University Hospital, Kloevervaenget 47, 5000 Odense C, Denmark. Hauptthemen laut MEDLINE: Chelating Agents, Radiopharmaceuticals, Cobalt, Peptides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Foundation, Novo Nordisk Foundation Interdisciplinary Synergy Programme 2022.
Abstract (Originalsprache)
The overexpression of the epidermal growth factor receptor (EGFR) in certain types of prostate cancers and glioblastoma makes it a promising target for targeted radioligand therapy. In this context, pairing an EGFR-targeting peptide with the emerging theranostic pair comprising the Auger electron emitter cobalt-58m (58mCo) and the Positron Emission Tomography-isotope cobalt-55 (55Co) would be of great interest for creating novel radiopharmaceuticals for prostate cancer and glioblastoma theranostics. In this study, GE11 (YHWYGYTPQNVI) was investigated for its EGFR-targeting potential when conjugated using click chemistry to N1-((triazol-4-yl)methyl)-N1,N2,N2-tris(pyridin-2-ylmethyl)ethane-1,2-diamine (TZTPEN). This chelator is suitable for binding Co2+ and Co3+. With cobalt-57 (57Co) serving as a surrogate radionuclide for 55/58mCo, the novel GE11-TZTPEN construct was successfully radiolabeled with a high radiochemical yield (99%) and purity (>99%). [57Co]Co-TZTPEN-GE11 showed high stability in PBS (pH 5) and specific uptake in EGFR-positive cell lines. Disappointingly, no tumor uptake was observed in EGFR-positive tumor-bearing mice, with most activity being accumulated predominantly in the liver, gall bladder, kidneys, and spleen. Some bone uptake was also observed, suggesting in vivo dissociation of 57Co from the complex. In conclusion, [57Co]Co-TZTPEN-GE11 shows poor pharmacokinetics in a mouse model and is, therefore, not deemed suitable as a targeting radiopharmaceutical for EGFR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Odense University Hospital, Kloevervaenget 47, 5000 Odense C, Denmark.
- Department of Clinical Research, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark.
- Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark.
ORCID-Profile: Aaraby Yoheswaran Nielsen, Mathias Lander Skavenborg, Niels Langkjær, Helge Thisgaard, Christine J McKenzie
Förderung
- Novo Nordisk Foundation
- Novo Nordisk Foundation Interdisciplinary Synergy Programme 2022
Zitieren
APA
Gé, L. G., Danielsen, M. B., Nielsen, A. Y., Skavenborg, M. L., Langkjær, N., Thisgaard, H., & McKenzie, C. J. (2025). Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics. Molecules. https://doi.org/10.3390/molecules30020212
Vancouver
Gé LG, Danielsen MB, Nielsen AY, Skavenborg ML, Langkjær N, Thisgaard H, et al. Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics. Molecules. 2025. doi:10.3390/molecules30020212
BibTeX
@article{G2025,
author = {Gé, Lorraine Gaenaelle and Danielsen, Mathias Bogetoft and Nielsen, Aaraby Yoheswaran and Skavenborg, Mathias Lander and Langkjær, Niels and Thisgaard, Helge and McKenzie, Christine J},
title = {Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30020212}
}
EUVIMED